Skip to content

Effect of continuous intravenous infusion of esketamine on the quality of recovery from general anesthesia, perioperative analgesia and long-term quality of life in patients undergoing thoracoscopic thoracic surgery

Effect of continuous intravenous infusion of esketamine on the quality of recovery from general anesthesia, perioperative analgesia and long-term quality of life in patients undergoing thoracoscopic thoracic surgery

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040885
Enrollment
Unknown
Registered
2020-12-13
Start date
2020-12-01
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracoscopic thoracic surgery

Interventions

High-dose esketamine group:After induction of anesthesia, continuous intravenous infusion of 0.25 mg / kg / h of esketmine was performed until chest closure began
control group:normal saline
Low-dose esketamine group:After induction of anesthesia, continuous intravenous infusion of 0.15mg / kg / h of esketmine was performed until chest closure began

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-70 years; 2. ASA grade I - II; 3. BMI 18.5-30; 4. Thoracoscopic lung surgery under general anesthesia; 5. Patients with postoperative patient-controlled intravenous analgesia pump (PCIA) treatment; 6. Patients or family members have a full understanding of the purpose and significance of this trial, and voluntarily participate in the clinical trial, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Chronic pain or opioid use before operation; 2. Drug allergy needed in this study; 3. Those who have mental illness and can't cooperate; 4. Inability to communicate due to cognitive impairment or language impairment before surgery; 5. Abnormal function of heart, liver and kidney; 6. Those who have mental illness and can't cooperate; 7. Blood pressure greater than or equal to 180 / 100mmhg; hypertension without treatment or poor control; 8. Glaucoma, intracranial hypertension, hyperthyroidism; 9. Alcoholics; 10. Other situations in which the investigator judged that the patient was not suitable to participate in the clinical trial.

Design outcomes

Primary

MeasureTime frame
Opioid consumption of perioperative patients;Recovery time of general anesthesia;Choking and restlessness during recovery;Recovery period delirium;The rest NRS scores after extubation and after operation: 1 h, 2 h, 4 h, 8 h, 12 h, 24 h, 48 h rest NRS scores;After extubation and postoperative exercise NRS score: 4h, 8h, 12h, 24h, 48h;

Secondary

MeasureTime frame
The time of the first analgesia and the times of additional analgesia after operation, and the dosage of drugs;The time of first exhaust, eating and getting out of bed were observed;Satisfaction score of patients with postoperative analgesia at 24 and 48 hours after operation;Sedation score, nausea and vomiting score and medication condition at 24 and 48 hours after operation;Postoperative hallucinations, nightmares, headache, drowsiness, pruritus, irritability, catheter irritation, respiratory depression, etc;Anxiety, depression and sleep were observed 24, 48 h, 1 W, 1 month and 3 months after operation;

Countries

China

Contacts

Public ContactJingjing Yuan

The First Affiliated Hospital of Zhengzhou University

yjingjing_99@163.com+86 13513719631

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026